What are the most common side effects of ketamine therapy?

The most frequently reported side effects include dissociation or altered perception, dizziness, nausea (affecting roughly 30 to 40 percent of patients), transient elevation in blood pressure and heart rate, blurred vision, fatigue, and headache. These effects are dose-dependent, typically mild to moderate at therapeutic doses, and resolve within 1 to 2 hours after treatment ends. Most patients tolerate ketamine well, especially after becoming familiar with the experience over multiple sessions.

Can ketamine therapy cause long-term damage?

At therapeutic doses administered under clinical protocols, long-term damage is not a well-documented concern. Bladder toxicity (ketamine cystitis) is associated with chronic heavy recreational use, not clinical treatment at standard frequencies. Cognitive effects at therapeutic doses appear minimal in available studies. Liver function can be affected at very high or prolonged recreational doses but has not been a significant concern in clinical treatment contexts. Ongoing research continues to monitor long-term outcomes.

Is ketamine addictive when used as therapy?

Ketamine is classified as a Schedule III controlled substance with recognized abuse potential. However, the risk of addiction in clinical therapeutic settings is considered low. Treatment protocols involve infrequent administration (typically weekly to monthly) under medical supervision, which differs fundamentally from patterns associated with recreational misuse. Providers screen for substance use history and monitor for signs of misuse. Patients with active substance use disorders may require additional precautions or alternative treatments.

Is at-home ketamine therapy safe?

At-home ketamine therapy using sublingual or oral formulations can be safe when proper protocols are followed. Key safety requirements include a prescribing provider who has conducted a thorough medical evaluation, a sober adult present during the session, video or phone monitoring by the prescribing provider or their team, no access to car keys or the ability to leave during treatment, clear instructions for emergency situations, and stable medical and psychiatric baseline. Patients with significant cardiovascular risk, severe dissociative responses, or complex psychiatric conditions are generally better served by in-clinic treatment.

Is Ketamine Therapy Safe? Understanding the Risks, Side Effects, and Safety Profile

Name: Ketamine Resource
Address: US
Price range: $$

The Safety Question

The question of whether ketamine therapy is safe is one of the most important and most frequently asked by patients and their families. It deserves a thorough, honest answer grounded in clinical evidence rather than marketing claims or unfounded fears.

The short answer is that ketamine therapy, when administered under appropriate medical supervision with proper patient screening and monitoring, has demonstrated an acceptable safety profile across hundreds of clinical studies and decades of clinical use. However, "acceptable safety" does not mean "risk-free," and understanding the specific risks, their likelihood, and how they are managed is essential for anyone considering this treatment.

Decades of Safety Data

Ketamine has one of the longest track records of any medication currently used in psychiatry, though most of that history comes from its role as an anesthetic. Since its FDA approval in 1970, ketamine has been used in millions of surgical procedures worldwide. The World Health Organization lists it as an essential medicine in part because of its exceptionally wide therapeutic index — the margin between an effective dose and a dangerous dose is larger than for most anesthetic agents.

The psychiatric application of ketamine at subanesthetic doses (typically 0.5 mg/kg for IV infusion, well below the 1-2 mg/kg range used for anesthesia) introduces a different risk profile. Research specifically examining the safety of low-dose ketamine for depression, anxiety, and chronic pain has been accumulating since the early 2000s, and the overall picture is reassuring.

A 2023 systematic review published in the Journal of Clinical Psychiatry examined safety data from over 60 clinical trials involving subanesthetic ketamine for psychiatric conditions. The review concluded that serious adverse events were rare, occurring in fewer than 1% of treated patients, and that the most common side effects were predictable, transient, and manageable.

Common Side Effects in Detail

Dissociation

Dissociation is the most characteristic effect of ketamine at therapeutic doses. Patients may experience feelings of detachment from their body or surroundings, altered perception of time (feeling as though time is slowing or accelerating), dreamlike or surreal mental states, changes in how the body feels (such as a sense of floating or heaviness), and visual or auditory perceptual changes.

These effects typically begin within 5 to 15 minutes of IV infusion onset, peak around 15 to 30 minutes, and resolve within 30 to 90 minutes after the infusion ends. The intensity varies by individual and dose. Many patients describe the experience as unusual but not unpleasant, particularly after the first session when they know what to expect.

For oral and sublingual formulations, dissociative effects tend to be milder due to lower bioavailability, though they can still occur at higher doses.

Nausea

Approximately 30% to 40% of patients experience some degree of nausea during or shortly after ketamine treatment. This is one of the more commonly bothersome side effects. Management strategies include pre-treatment with ondansetron (Zofran) or other anti-nausea medications, fasting for four to six hours before the session, ginger-based remedies as a complementary approach, and slower infusion rates for IV delivery.

Most patients who experience nausea during their first session find that it decreases with subsequent treatments as the body becomes accustomed to the medication.

Cardiovascular Effects

Ketamine produces transient increases in blood pressure and heart rate. Typical elevations include systolic blood pressure increasing by 15 to 25 mmHg, diastolic blood pressure increasing by 10 to 15 mmHg, and heart rate increasing by 10 to 20 beats per minute.

These elevations are temporary, usually peaking within 30 to 40 minutes and returning to baseline within 1 to 2 hours. For most patients, these changes are clinically insignificant. However, they are the primary reason that uncontrolled hypertension is a contraindication for ketamine therapy.

Blood pressure and heart rate are monitored before, during, and after each in-clinic session. If blood pressure exceeds acceptable thresholds, the infusion rate can be slowed or stopped, and antihypertensive medications can be administered if necessary.

Other Common Effects

Additional side effects that patients may experience include dizziness or lightheadedness (reported by approximately 20-30% of patients), blurred vision or double vision during treatment, headache (usually mild and responsive to over-the-counter analgesics), fatigue or drowsiness following the session, and increased salivation or dry mouth.

Serious Risks and How They Are Managed

Cardiovascular Events

The most significant acute medical risk of ketamine therapy involves cardiovascular events in patients with underlying cardiovascular disease. The temporary elevation in blood pressure and heart rate could theoretically precipitate a hypertensive crisis, angina, arrhythmia, or in extreme cases, stroke or myocardial infarction in vulnerable individuals.

This risk is managed through pre-treatment cardiovascular screening, continuous blood pressure and heart rate monitoring during treatment, exclusion of patients with uncontrolled hypertension or significant cardiac disease, and availability of antihypertensive medications during sessions. When these precautions are observed, cardiovascular complications during ketamine therapy are exceedingly rare in the published literature.

Psychological Distress

A small percentage of patients experience significant psychological distress during ketamine sessions, which may manifest as intense anxiety or panic, frightening visual or auditory experiences, feelings of losing control, and paranoid ideation.

These experiences are more likely at higher doses and in patients with a predisposition to anxiety or certain personality traits. They are managed through verbal reassurance and guided relaxation by clinical staff, dose reduction for subsequent sessions, pre-treatment with low-dose benzodiazepine if appropriate (though this may reduce ketamine's efficacy), and careful evaluation of whether continued ketamine treatment is appropriate.

Respiratory Depression

At anesthetic doses, ketamine can suppress breathing. At the subanesthetic doses used in psychiatric treatment (typically one-quarter to one-half of anesthetic doses), respiratory depression is extremely rare. This is one of the safety advantages of ketamine compared to other sedative medications. Nonetheless, pulse oximetry monitoring is standard practice during in-clinic sessions.

Emergence Reactions

Some patients experience vivid, sometimes disturbing mental imagery or confusion during the transition from the ketamine experience back to normal consciousness. This phenomenon, sometimes called emergence delirium, is more common with higher doses and in certain patient populations. It is typically brief and self-limiting.

Contraindications

Not everyone is a candidate for ketamine therapy. The following conditions represent absolute or relative contraindications.

Absolute Contraindications

Patients with uncontrolled high blood pressure (generally defined as systolic greater than 180 mmHg or diastolic greater than 110 mmHg at rest), active psychotic disorders including schizophrenia and schizoaffective disorder, current substance use disorder involving ketamine or phencyclidine (PCP), untreated hyperthyroidism, significantly elevated intracranial pressure, and pregnancy should not receive ketamine therapy.

Relative Contraindications

Conditions that require careful evaluation and may preclude treatment in some cases include poorly controlled but treated hypertension, a history of psychotic episodes (even if currently in remission), active manic episodes, severe liver disease, unstable cardiovascular disease, and a history of aneurysms.

Medication Interactions

Certain medications may interact with ketamine. Benzodiazepines may reduce ketamine's antidepressant efficacy. Lamotrigine may diminish ketamine's therapeutic effects through its action on glutamate signaling. MAOIs (monoamine oxidase inhibitors) may potentiate ketamine's cardiovascular effects. Patients should disclose all current medications to their ketamine provider.

Long-Term Safety Considerations

Bladder Health

Ketamine-associated cystitis is a well-documented condition in chronic heavy recreational users, characterized by bladder inflammation, pain, urinary frequency, and in severe cases, bladder fibrosis. This condition is associated with daily or near-daily use of large doses over months to years.

Clinical ketamine therapy involves far lower doses and frequencies. Published studies of patients receiving therapeutic ketamine for depression over periods of months to years have not demonstrated clinically significant urological complications. Providers monitor for urinary symptoms as a precaution, and any emerging urinary complaints prompt evaluation and potential treatment modification.

Cognitive Effects

Concern about cognitive impairment is understandable given ketamine's mechanism of action on brain receptors. Studies examining cognitive function in patients receiving therapeutic ketamine have generally found that any cognitive effects (such as mild memory difficulties or reduced concentration) are transient, resolving within hours of each session. Long-term cognitive testing in patients on maintenance ketamine protocols has not revealed cumulative impairment in most studies, though long-term data remains limited.

Dependence and Tolerance

Ketamine is a Schedule III controlled substance, and the potential for dependence exists. In clinical settings, the risk is mitigated by infrequent dosing schedules (typically weekly to monthly), medical oversight and structured treatment protocols, screening for substance use history, and ongoing monitoring for signs of escalating use or psychological dependence.

Tolerance — the need for increasing doses to achieve the same effect — can develop with frequent use. Clinical protocols that space treatments appropriately help minimize tolerance development. If tolerance does emerge, a temporary pause in treatment followed by resumption at a lower frequency often restores responsiveness.

Safety Across Different Treatment Settings

In-Clinic IV Infusion

In-clinic settings provide the highest level of safety monitoring, including continuous vital sign tracking, immediate access to emergency medications and equipment, direct observation by clinical staff, and controlled environment free from external hazards.

In-Clinic Spravato

The FDA-mandated REMS program for Spravato requires two hours of post-dose monitoring in a certified facility, vital sign assessment before and after treatment, supervision by a healthcare provider, and the patient not driving until the following day.

At-Home Oral and Sublingual

At-home treatment requires additional safety precautions to compensate for the absence of in-person clinical monitoring. Standard requirements include a sober adult observer present throughout the session, video or telephone monitoring by the prescribing provider or their clinical team, removal of car keys and any means of leaving during treatment, a safe physical environment free from trip hazards and sharp objects, clear written instructions for what to do in an emergency, and no concurrent use of alcohol, sedatives, or other substances.

Making an Informed Decision

The safety profile of ketamine therapy is favorable compared to many existing psychiatric treatments, but it is not zero-risk. The following principles can help ensure the safest possible experience:

Choose a qualified provider. Look for providers with specific training and experience in ketamine therapy, not simply any provider willing to prescribe it — see our guide on finding a qualified provider. Board certification in psychiatry, anesthesiology, or pain medicine is a positive indicator.

Complete a thorough screening. A comprehensive medical and psychiatric evaluation before treatment is non-negotiable. Providers who skip this step or rush through it are not following best practices.

Follow the protocol. Adherence to recommended dosing, timing, and monitoring guidelines is essential. Self-adjusting doses or frequency without provider guidance increases risk.

Report side effects. Open communication with your treatment team about any adverse effects, even ones that seem minor, allows for appropriate adjustments and prevents potential complications.

Maintain realistic expectations. Understanding that ketamine therapy involves managed medical risk — not a risk-free experience — helps patients approach treatment with appropriate awareness and preparation.

Important: If you are considering ketamine therapy, discuss your full medical history, current medications, and any concerns openly with a qualified healthcare provider. Safety in ketamine therapy depends above all on thorough evaluation, proper monitoring, and a trusting provider-patient relationship.

References

StatPearls: Ketamine — Comprehensive clinical reference covering ketamine's safety profile, adverse effects, and contraindications
Short B, et al. (2018). Side-effects Associated with Ketamine Use in Depression. Lancet Psychiatry — Systematic review of adverse effects across multiple clinical trials of ketamine for depression
FDA: Spravato REMS — FDA Risk Evaluation and Mitigation Strategy program for esketamine including safety monitoring requirements
NIMH: Depression — National Institute of Mental Health information on depression treatment including emerging therapies and safety considerations
WHO Model List of Essential Medicines — World Health Organization essential medicines list recognizing ketamine's safety and therapeutic value
Mayo Clinic: Ketamine Treatment for Depression — Mayo Clinic overview of esketamine treatment including safety information and what to expect